Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Biosimilars Business Strategies

Lupin: Glad To Have Dodged Humira Bullet, Lucentis Biosimilar Closer As Phase III Trials Succeed

Amazon, Mark Cuban Not Upset US Market Dynamics

  • Analysis

Executive Summary

Lupin’s CEO highlights market access strategy as a key tool to ensure biosimilars success in the US while being relieved the company didn’t launch a Humira biosimilar. She also mentions Amazon and Mark Cuban have not upset market dynamics for generics in the US and a Lucentis biosimilar is closer to a global launch post Phase III trial success

Table

View full table

Related Content

Scrip
Scrip
Generics Bulletin
Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Commercial Biosimilars Business Strategies
Latest Headlines

Pipeline Watch: 11 Approvals And Seven Phase III Readouts

10 Approvals To Watch Out For In Q3

Lupin: Glad To Have Dodged Humira Bullet, Lucentis Biosimilar Closer As Phase III Trials Succeed

Northeast’s DCTY Deal Marks China’s First Domestic Biotech Acquisition Of '24

See All
UsernamePublicRestriction

Register

SC150726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By